Lumicell nabs FDA approval for drug-device breast cancer detection system

The Mass­a­chu­setts-based biotech Lu­mi­cell won FDA ap­proval on Thurs­day for its drug-de­vice com­bi­na­tion prod­uct used to help de­tect resid­ual can­cer in breast can­cer pa­tients, the FDA an­nounced.

The com­bo of both the op­ti­cal imag­ing agent peg­uli­cia­n­ine and the com­pa­ny’s Di­rect Vi­su­al­iza­tion Sys­tem or an­oth­er flu­o­res­cence imag­ing de­vice al­lows sur­geons to scan for and re­move resid­ual can­cer that may oth­er­wise go un­de­tect­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.